Our Mission

Pipeline

Our Focus

We are advancing a wholly-owned portfolio of oral small molecule GPCR-targeted programs focused initially on treating patients with significant unmet needs in endocrinology, immunology and inflammation, and metabolic disease.

For each program we utilize our Native Complex Platform™ to discover lead candidates with mechanisms of action designed to have disease-modifying potential, and we have prioritized programs with biomarker-driven early clinical readouts.

Pipeline

Scroll sideways to view more.

Program

Development Status

Program / Target

Mode of Action

Therapeutic Area

Indications

Discovery

IND-enabling

Phase 1

Phase 2

Phase 3

SEP-786 (PTH1R)

Oral Small Molecule PTH1R Agonist for Hypoparathyroidism

SEP-631 (MRGPRX2)

Oral Small Molecule MRGPRX2 NAM for CSU and Other Mast Cell Diseases

TSHR Program

Oral Small Molecule TSHR NAM for Graves’ Disease and TED

GLP-1R, GIPR, GCGR Program

Obesity, T2D and other metabolic diseases

PTH1R = Parathyroid Hormone 1 Receptor
TSHR = Thyroid-Stimulating Hormone Receptor
MRGPRX2 = MAS-Related G Protein-Coupled Receptor X2
GLP-1R = Glucagon-Like Peptide 1 Receptor.
GIPR = Gastric Inhibitory Polypeptide Receptor
GCGR = Glucagon Receptor

The Details

Programs
Additional Information

SEP-786 (PTH1R)

SEP-786 (PTH1R)

Clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism that could offer a convenient, functional replacement for PTH for all hypoparathyroidism patients.

SEP-631 (MRGPRX2)

SEP-631 (MRGPRX2)

Oral small molecule  negative allosteric modulator (NAM) that inhibits MRGPRX2 and could provide a differentiated treatment option for patients with chronic spontaneous urticaria (CSU) and other mast cell driven diseases.

TSHR Program

TSHR Program

Oral small molecule thyroid-stimulating hormone receptor (TSHR) NAM that could offer a novel disease-modifying treatment approach for both Graves’ Disease and Thyroid Eye Disease.

GLP-1R, GIPR, GCGR Program

GLP-1R, GIPR, GCGR Program

Potential novel, next-generation, oral small molecule single- or multi-acting agonists of the GLP-1, GIPR, glucagon receptors for patients with obesity, diabetes and other metabolic diseases.

The Details

Publications